Business Wire

NY-HCL-GROUP

20.9.2022 23:45:31 CEST | Business Wire | Press release

Share
HCL and UpLink Call for Applications Globally for Aquapreneur Innovation Initiative

HCL, a global conglomerate and UpLink, the open innovation platform of the World Economic Forum, announced today that applications have opened for the Global Freshwater Innovation Challenge. This is the first out of five Challenges of the HCL and UpLink’s Aquapreneur Innovation Initiative, a programme to source innovative solutions to conserve and restore freshwater ecosystems, from ‘aquapreneurs’ (water focused entrepreneurs). The Initiative, launched during the Forum’s Annual Meeting in Davos in May 2022, will create a first-of-its-kind innovation ecosystem for the global freshwater sector. The last date to apply is November 08, 2022. Full details and eligibility criteria can be found at this link. HCL has committed $15 million over five years to support the water focused entrepreneurs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220920005992/en/

Roshni Nadar Malhotra, Chairperson of HCL Technologies said, “An innovation ecosystem can enable water entrepreneurs with resources and mentoring to invest in creating new solutions and improving any existing ones for scale and impact. There are entrepreneurs and start-ups that have the potential to provide contextualized solutions to conserve freshwater and have been trying to create impact in small ways within small ecosystems. Out of these, many struggle to secure financing and lack the operational capacity to scale their solutions. HCL, through its large network and partnership with the World Economic Forum’s UpLink, is keen to ensure that these entrepreneurs are identified and supported.”

The first year’s challenge, called the Global Freshwater Challenge, will focus on:

  • Improved decision-making: solutions that fill knowledge gaps, improve data collection, and create transparent and accessible data (i.e., solutions that monitor and forecast water use & demand)
  • Water quality restoration: solutions that tackle water quality by monitoring, treating, restoring or protecting it. (i.e. solutions such as solar distillers for water purification)
  • Ecosystem resilience: solutions that protect source waters across the value chain and strengthen resilience to climate and weather-related shocks, taking into consideration the most vulnerable areas at risk (i.e. solutions that reduce water evapotranspiration from extreme heat, or ways to absorb and store acute flooding)

Gim Huay Neo, Managing Director of the Centre for Nature and Climate at the World Economic Forum says, “The Aquapreneur Innovation Initiative invites all entrepreneurs to participate to scale and accelerate their solutions and impact. Through this initiative, we seek to enhance freshwater resilience and better protect our water resource. The collaboration with HCL and UpLink will provide a platform for the top innovators to connect with public and private partners, as well as gain access to venture funds, to jointly transform our sustainable management and use of freshwater systems.”

HCL and UpLink are looking for:

  • Stage: Impact-oriented start-ups that are at pilot, growth or scale-up phase, with demonstrated success towards scale (i.e., a proven track record with measurable results and impact). Solutions that represent an “idea” or “prototype” phase will not be considered.
  • Business Model: Ideally seeking for-profit start-up companies or social enterprises with a sustainable, and ideally hybrid, funding model.
  • Scale: Start-ups which demonstrate the potential to scale, particularly for communities most impacted, alongside a vision for achieving long-term financial viability and sustainability.

Selected entrepreneurs will have the opportunity to work closely with industry experts, investors, and ecosystem partners to further develop their innovative solution, to scale and drive further impact.

About HCL Group

Founded in 1976 as one of India’s original IT garage start-ups, HCL is a pioneer of modern computing with many firsts to its credit, including the introduction of the 8-bit microprocessor-based computer in 1978 well before its global peers. Today, the HCL Group has business presence across sectors including technology and healthcare and comprises three group companies – HCL Technologies, HCL Infosystems and HCL Healthcare. The Group generates annual revenues of over US$11.8 billion with more than 211,000 employees operating across 52 countries.

HCL Technologies, a group company, empowers global enterprises with technology for the next decade, today. As a leading global technology company, it takes pride in its diversity, social responsibility, sustainability and education initiatives. HCL Technologies is also a strategic partner of the World Economic Forum.

About UpLink

UpLink is the open innovation platform of the World Economic Forum, dedicated to unlocking an ‘entrepreneur revolution’ to support positive systemic change for people and planet. Launched at the Forum’s Annual Meeting in Davos in January 2020 in collaboration with Salesforce and Deloitte, UpLink is now a thriving ecosystem of 50,000+ entrepreneurs, investors and experts, who are collaborating around innovation for the UN Sustainable Development Goals.

For further information, visit www.hcl.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005992/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye